Electrospun Fibers Loaded with Pirfenidone: An Innovative Approach for Scar Modulation in Complex Wounds

Bioinspired Janus Membrane with Dopamine-ZnO Coating for Antibacterial Filtration in Oral Applications

Developing an oral fibrous barrier membrane that prevents bacterial invasion while possessing antibacterial properties and facilitating fluid decompression remains a significant clinical and scientific challenge. In this study, we developed a novel Janus membrane by modifying a polypropylene (PP) fibrous membrane with dopamine and zinc oxide nanoparticles (ZnO-NPs). Fabricated via a simple floating immersion method, this asymmetric bilayer structure consists of a hydrophobic PP layer and a hydrophilic PP/dopamine@30 nm ZnO layer, providing both antibacterial properties and enhanced fluid filtration. The mechanical properties of the PP/ZnO membrane were significantly enhanced, with an increase in the Young's modulus and ultimate tensile strength, indicating improved strength. Antibacterial activity against Streptococcus mutans (S. mutans) demonstrated a significant reduction in biofilm formation on the PP/dopamine@30 nm ZnO surface compared to unmodified PP. Water flux tests confirmed a stable, high filtration rate, with increased permeability under rising pressure. In vivo experiments with miniature pigs confirmed reduced bacterial presence on the sterile side of the membrane. These findings highlight the potential of the membrane for oral exudate filtration, extending filtration time and minimizing infection risks under strict sterility conditions. Further improvements in barrier properties are necessary to optimize its clinical performance.

The role of macrophages in hypertrophic scarring: molecular to therapeutic insights

Hypertrophic Scar (HS) is a common fibrotic disease of the skin, usually caused by injury to the deep dermis due to trauma, burns, or surgical injury. The main feature of HS is the thickening and hardening of the skin, often accompanied by itching and pain, which seriously affects the patient's quality of life. Macrophages are involved in all stages of HS genesis through phenotypic changes. M1-type macrophages primarily function in the early inflammatory phase by secreting pro-inflammatory factors, while M2-type macrophages actively contribute to tissue repair and fibrosis. Despite advances in understanding HS pathogenesis, the precise mechanisms linking macrophage phenotypic changes to fibrosis remain incompletely elucidated. This review addresses these gaps by discussing the pathological mechanisms of HS formation, the phenotypic changes of macrophages at different stages of HS formation, and the pathways through which macrophages influence HS progression. Furthermore, emerging technologies for HS treatment and novel therapeutic strategies targeting macrophages are highlighted, offering potential avenues for improved prevention and treatment of HS.

Dual Drug-Loaded Coaxial Nanofiber Dressings for the Treatment of Diabetic Foot Ulcer

Introduction

Diabetes mellitus is frequently associated with foot ulcers, which pose significant health risks and complications. Impaired wound healing in diabetic patients is attributed to multiple factors, including hyperglycemia, neuropathy, chronic inflammation, oxidative damage, and decreased vascularization.

Rationale

To address these challenges, this project aims to develop bioactive, fast-dissolving nanofiber dressings composed of polyvinylpyrrolidone loaded with a combination of an antibiotic (moxifloxacin or fusidic acid) and anti-inflammatory drug (pirfenidone) using electrospinning technique to prevent the bacterial growth, reduce inflammation, and expedite wound healing in diabetic wounds.

Results

The fabricated drug-loaded fibers exhibited diameters of 443 ± 67 nm for moxifloxacin/pirfenidone nanofibers and 488 ± 92 nm for fusidic acid/pirfenidone nanofibers. The encapsulation efficiency, drug loading and drug release studies for the moxifloxacin/pirfenidone nanofibers were found to be 70 ± 3% and 20 ± 1 µg/mg, respectively, for moxifloxacin, and 96 ± 6% and 28 ± 2 µg/mg, respectively, for pirfenidone, with a complete release of both drugs within 24 hours, whereas the fusidic acid/pirfenidone nanofibers were found to be 95 ± 6% and 28 ± 2 µg/mg, respectively, for fusidic acid and 102 ± 5% and 30 ± 2 µg/mg, respectively, for pirfenidone, with a release rate of 66% for fusidic acid and 80%, for pirfenidone after 24 hours. The efficacy of the prepared nanofiber formulations in accelerating wound healing was evaluated using an induced diabetic rat model. All tested formulations showed an earlier complete closure of the wound compared to the controls, which was also supported by the histopathological assessment. Notably, the combination of fusidic acid and pirfenidone nanofibers demonstrated wound healing acceleration on day 8, earlier than all tested groups.

Conclusion

These findings highlight the potential of the drug-loaded nanofibrous system as a promising medicated wound dressing for diabetic foot applications.